Filing Analysis
Akebia Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2024, and recent business highlights.
📋 Key Facts
- Report date: November 7, 2024
- Reporting period: Quarter ended September 30, 2024
- The filing includes a press release (Exhibit 99.1) containing financial results and business highlights.
Akebia Therapeutics, Inc. has entered into a multi-year commercial supply agreement with a leading dialysis organization to provide access to its product Vafseo® (vadadustat) for patients undergoing dialysis.
📋 Key Facts
- Agreement Date: October 22, 2024
- Product involved: Vafseo® (vadadustat)
- Counterparty: A leading dialysis organization
- Term: Multi-year commercial supply agreement
Akebia Therapeutics has entered into an amendment to its existing Supply Agreement with STA Pharmaceutical Hong Kong Limited. The amendment extends the manufacturing term for vadadustat and modifies pricing structures.
📋 Key Facts
- Amendment #1 to the Supply Agreement was executed on October 15, 2024.
- The term of the agreement is extended until January 1, 2032.
- The amendment includes changes to the volume-based pricing structure for vadadustat drug product.
- STA Pharmaceutical Hong Kong Limited remains the manufacturer for the Product.
Akebia Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2024, and provided recent business highlights via a press release.
📋 Key Facts
- Report date: August 8, 2024
- Reporting period: Quarter ended June 30, 2024
- The filing includes results of operations and financial condition (Item 2.02).
- A press release was issued as Exhibit 99.1.
Akebia Therapeutics terminated its exclusive license agreement with CSL Vifor for the product Vafseo, transitioning to a royalty-based settlement model. The company also amended its $55 million senior secured loan facility with Kreos Capital (BlackRock) in connection with this termination.
🚩 Red Flags
- Significant cash outflow obligations: The company faces mandatory 'True-Up' payments totaling up to $40M by 2028, creating significant liquidity pressure.
- Complex royalty structures and potential for high long-term cost of goods/sales due to multiple layers of royalties (WCF and Settlement).
- The termination is linked to loan covenant amendments, suggesting the restructuring impacts existing debt terms.
📋 Key Facts
- Termination of Second Amended and Restated License Agreement with CSL Vifor effective July 10, 2024.
- Akebia must repay a $40 million Working Capital Fund via tiered royalty payments (8% to 14%) starting July 1, 2025, through May 31, 2028.
- Mandatory 'True-Up' payments of $10M, $20M, and $40M are required on May 31 of 2026, 2027, and 2028 if cumulative royalties are insufficient.
- Additional Settlement Royalty Payments apply to Vafseo sales in the U.S. territory until patent/regulatory exclusivity expires.
- Akebia has a 'Royalty Buy-Down Option' starting July 1, 2027, to reduce settlement royalty rates.
- Amended existing $55 million senior secured term loan facility with Kreos Capital VII (UK) Limited.
Akebia Therapeutics, Inc. announced the appointment of Erik Ostrowski as Senior Vice President, CFO, CBO, Treasurer, and principal financial officer, effective June 24, 2024.
📋 Key Facts
- Erik Ostrowski appointed as SVP, CFO, Chief Business Officer, Treasurer, and principal financial officer.
- Effective date of appointment is June 24, 2024.
- Base salary set at $540,000 per year with an annual bonus target of up to 45% of base salary.
- Equity compensation includes 500,000 stock options (4-year vesting) and 350,000 RSUs (3-year vesting).
- Mr. Ostrowski previously served as President/Interim CEO/CFO at AVROBIO, Inc.
Akebia Therapeutics, Inc. held its Annual Meeting of Stockholders on June 6, 2024. The meeting resulted in the election of three Class I directors and the ratification of Ernst & Young LLP as independent auditors, though a proposal to increase shares under the 2023 Stock Incentive Plan was rejected.
🚩 Red Flags
- Shareholders rejected the proposal to increase the share pool in the 2023 Stock Incentive Plan, which may indicate investor dissatisfaction with dilution or current compensation structures.
📋 Key Facts
- Annual Meeting held on June 6, 2024.
- Three Class I directors (Ronald E. Frieson, Steven C. Gilman, Ph.D., and Cynthia Smith) were elected to serve until the 2027 annual meeting.
- The proposal to increase common stock available under the 2023 Stock Incentive Plan by 9,800,000 shares was NOT approved (52,820,792 votes against vs. 45,155,875 for).
- Say-on-pay advisory vote regarding executive compensation was approved.
- Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2024 was approved.
Akebia Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended March 31, 2024, and provided recent business highlights via a press release.
📋 Key Facts
- Report date: May 9, 2024
- Reporting period: Quarter ended March 31, 2024
- The filing includes results of operations and financial condition (Item 2.02)
- Press release issued as Exhibit 99.1
Akebia Therapeutics has drawn down a portion of its existing senior secured term loan facility with Kreos Capital VII (UK) Limited. The company received $7.5 million in net proceeds on April 19, 2024, following the drawdown of Tranche B.
🚩 Red Flags
- Continued reliance on debt financing to fund operations/liquidity.
- The drawdown of specific tranches suggests active management of cash runway.
📋 Key Facts
- The Company drew down the 'Tranche B Loan' portion of its existing loan facility on April 17, 2024.
- Net proceeds received were $7.5 million on April 19, 2024 (after deducting fees and expenses).
- The total Term Loan Facility has an aggregate principal amount of up to $55.0 million.
- Initial tranche of $37.0 million was funded on January 29, 2024.
- A remaining $10.0 million in borrowing capacity (Tranche C) remains available under the agreement.
Akebia Therapeutics entered into Amendment #2 to its Supply Agreement with STA Pharmaceutical Hong Kong Limited. The amendment extends the manufacturing agreement for vadadustat drug substance by five years and modifies the volume-based pricing structure.
📋 Key Facts
- Amendment #2 to the Supply Agreement was executed on April 15, 2024.
- The term of the Supply Agreement is extended by five years, now expiring on April 2, 2029.
- The amendment includes changes to the volume-based pricing structure for vadadustat drug substance.
- STA Pharmaceutical Hong Kong Limited remains the manufacturer for commercial purposes.
Akebia Therapeutics announced that the FDA has approved its New Drug Application (NDA) for Vafseo® (vadadustat) tablets. The drug is indicated for treating anemia in adults with chronic kidney disease who have been receiving dialysis for at least three months.
📋 Key Facts
- FDA approval received on March 27, 2024.
- Product: Vafseo® (vadadustat) tablets.
- Indication: Treatment of anemia due to chronic kidney disease in adults receiving dialysis for at least three months.
Akebia Therapeutics announced the departure of its Senior Vice President, Chief Financial Officer (CFO), and Treasurer, Ellen Snow, effective March 22, 2024. CEO John Butler will serve as the interim principal financial officer following her transition.
🚩 Red Flags
- Sudden departure of a CFO in a micro-cap/biotech environment can sometimes signal internal friction or financial reporting concerns, though no restatement was noted here.
- Interim leadership (CEO acting as PFO) can create operational strain and delays in financial oversight.
📋 Key Facts
- Ellen Snow to transition from CFO role on March 22, 2024.
- Departure is by mutual agreement.
- Severance includes 12 months of base salary continuation and up to 12 months of COBRA premium reimbursement.
- Unvested equity awards will continue to vest during the severance period.
- John Butler (CEO) will assume the role of interim principal financial officer.
Akebia Therapeutics, Inc. filed an 8-K to announce its financial results for the fourth quarter and fiscal year ended December 31, 2023, alongside business updates.
📋 Key Facts
- Report date: March 14, 2024
- Reporting period: Fourth quarter and fiscal year ended December 31, 2023
- The filing includes a press release (Exhibit 99.1) containing financial results and business updates.
Akebia Therapeutics announced amendments to the separation agreements for its Chief Operating Officer, Michel Dahan, and Senior Vice President/Chief Legal Officer, Nicole R. Hadas. Both executives have agreed to extend their effective separation dates into mid-to-late 2024.
🚩 Red Flags
- Successive delays in executive departures can sometimes indicate transition friction or ongoing litigation/disputes, though not explicitly stated here.
📋 Key Facts
- Michel Dahan (COO) separation date extended from March 22, 2024, to June 28, 2024.
- Nicole R. Hadas (SVP, CLO) separation date extended from March 29, 2024, to June 14, 2024.
- The extensions were agreed upon on February 8, 2024.
- Separation dates could potentially extend as far as September 22, 2024, depending on specified events.
Akebia Therapeutics entered into a $55 million senior secured term loan facility with Kreos Capital VII (managed by BlackRock) to replace an existing Pharmakon loan. The financing includes significant warrant coverage and is heavily contingent upon FDA approval of the company's drug, vadadustat.
🚩 Red Flags
- High interest rate environment (SOFR + 6.75%) with a significant default penalty (+3.0% spread).
- Significant dilution risk via warrants totaling over 4.2 million shares.
- Heavy dependency on FDA approval of vadadustat to avoid accelerated repayment and extend maturity.
- Strict financial covenant requiring $15M minimum cash balance.
📋 Key Facts
- Entered into a $55.0 million senior secured term loan facility with Kreos Capital VII (UK) Limited on January 29, 2024.
- Initial tranche of $37.0 million funded immediately; net proceeds approximately $34.5 million after fees.
- Additional tranches: $8.0M (Tranche B) and $10.0M (Tranche C), both contingent on FDA approval of vadadustat.
- Interest rate is SOFR + 6.75% (floor 4.25%, cap 15.00%).
- Warrant issuance: 3,076,923 shares at $1.30 exercise price; additional 1,153,846 shares contingent on Tranche C drawdown.
- Maturity date is March 31, 2025, but extends to January 29, 2028, if vadadustat receives FDA approval by June 30, 2024.
- Financial covenant requires maintaining $15 million in cash or $150 million in trailing twelve-month revenue.
Akebia Therapeutics, Inc. announced the appointment of Richard C. Malabre as Chief Accounting Officer and principal accounting officer, effective January 8, 2024.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Richard C. Malabre appointed as Chief Accounting Officer (CAO) and principal accounting officer on Jan 8, 2024.
- Malabre will report to Ellen Snow, SVP, CFO, Treasurer, and principal financial officer.
- Compensation includes a $380,000 annual base salary and an annual cash bonus target of up to 35% of base salary.
- Equity grants include 336,000 stock options (4-year vesting) and 223,950 Restricted Stock Units (RSUs) (3-year vesting).
- Malabre previously served as CFO at Ultivue, Inc. and VP/Corporate Controller at Oxford Immunotec USA, Inc.
Akebia Therapeutics announced its intention to present preliminary unaudited net product revenue for Auryxia® at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024.
📋 Key Facts
- CEO John P. Butler will present at the J.P. Morgan Healthcare Conference on Jan 11, 2024, at 11:15 a.m. PST.
- Presentation includes preliminary unaudited net product revenue for Auryxia® (cumulative and fiscal year ended Dec 31, 2023).
- Management will also hold various investor and analyst meetings starting January 8, 2024.